New Scaffolds of Proteasome Inhibitors: Boosting Anticancer Potential by Exploiting the Synergy of In Silico and In Vitro Methodologies

Cancer is a complex multifactorial disease whose pathophysiology involves multiple metabolic pathways, including the ubiquitin–proteasome system, for which several proteasome inhibitors have already been approved for clinical use. However, the resistance to existing therapies and the occurrence of s...

Descripción completa

Detalles Bibliográficos
Autores principales: Guedes, Romina A., Grilo, Jorge H., Carvalho, Andreia N., Fernandes, Pedro M. P., Ressurreição, Ana S., Brito, Vanessa, Santos, Adriana O., Silvestre, Samuel, Gallerani, Eleonora, Gama, Maria João, Gavioli, Riccardo, Salvador, Jorge A. R., Guedes, Rita C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458307/
https://www.ncbi.nlm.nih.gov/pubmed/37631011
http://dx.doi.org/10.3390/ph16081096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458307/
https://www.ncbi.nlm.nih.gov/pubmed/37631011
http://dx.doi.org/10.3390/ph16081096

Ejemplares similares